Stock EPRX EUPRAXIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Eupraxia Pharmaceuticals Inc. Share Price

Equities

EPRX

CA29842P1053

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 01:26:52 30/04/2024 am IST 		5-day change 1st Jan Change
3.68 CAD -1.34% Intraday chart for Eupraxia Pharmaceuticals Inc. -8.91% -31.47%
08/04 Top Premarket Decliners MT
08/04 Eupraxia Pharmaceuticals Inc.(NasdaqCM:EPRX) added to NASDAQ Composite Index CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 133M 97.27M 8.11B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 29
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.3%
More Fundamentals * Assessed data

Chart Eupraxia Pharmaceuticals Inc.

Dynamic Chart

Latest news about Eupraxia Pharmaceuticals Inc.

Top Premarket Decliners MT
Eupraxia Pharmaceuticals Inc.(NasdaqCM:EPRX) added to NASDAQ Composite Index CI
Eupraxia Pharmaceuticals Inc. Brief: Begins Trading on Nasdaq Today MT
Eupraxia Pharmaceuticals Inc. Brief: Says to Begin Trading on Nasdaq on April 5, 2024 MT
Eupraxia Pharmaceuticals Inc. Brief: Says incurred a net loss of US$10.6 million for Q4, versus $7.8 million for the three months ended December 31, 2022 MT
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Eupraxia Pharmaceuticals Completes Overnight Marketed Offering MT
Toronto Stocks Edge Forward; Shares of Altius Minerals Rise on 4Q Revenue Beat DJ
Eupraxia Pharmaceuticals Prices Overnight Marketed Offering of C$30 Million MT
Eupraxia Pharmaceuticals Seeking C$30 Million in an Overnight Marketed Share Offering MT
Update on Eupraxia Pharmaceuticals Announcing Updated "Positive" Clinical Data in EP-104GI RESOLVE Trial for Treatment of Eosinophilic Esophagitis MT
Eupraxia Pharmaceuticals Announcing Updated "Positive" Clinical Data in EP-104GI RESOLVE Trial for Treatment of Eosinophilic Esophagitis MT
Eupraxia Pharmaceuticals Inc. Brief: Announcing Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis MT
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis CI
Eupraxia Pharmaceuticals Initiated Phase 3 Development Program for EP-104IAR MT
More news

Analyst Recommendations on Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Rated Outperform, $7 Target Price at Raymond James MT
More recommendations

Press releases Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals : Name and Address of Company - Form 6-K PU
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference PR
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today PR
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024 PR
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024 AQ
More press releases

Quotes and Performance

1 day-1.34%
1 week-8.91%
Current month-13.41%
1 month-9.80%
3 months-29.23%
6 months-28.54%
Current year-31.47%
More quotes

Highs and lows

1 week
3.68
Extreme 3.68
4.12
1 month
3.44
Extreme 3.44
4.79
Current year
3.44
Extreme 3.44
7.64
1 year
3.44
Extreme 3.44
9.10
3 years
0.80
Extreme 0.8
9.10
5 years
0.80
Extreme 0.8
9.10
10 years
0.80
Extreme 0.8
9.10
More quotes

Managers and Directors - Eupraxia Pharmaceuticals Inc.

Managers TitleAgeSince
James A. Helliwell FOU
 Founder - 23/12/23
Bruce G. Cousins DFI
 Director of Finance/CFO 63 03/21/03
Amanda Malone CTO
 Chief Tech/Sci/R&D Officer - 01/12/01
Members of the board TitleAgeSince
Paul Geyer BRD
 Director/Board Member 61 14/13/14
John Montalbano FOU
 Founder 59 01/12/01
Richard Glickman BRD
 Director/Board Member 65 09/21/09
More insiders

Quotes

Date Price Change Volume
30/24/30 3.68 -1.34% 22 422
26/24/26 3.73 -4.36% 15,050
25/24/25 3.9 -0.76% 6,000
24/24/24 3.93 -0.76% 28,910
23/24/23 3.96 -1.98% 32,606

Delayed Quote Toronto S.E., April 30, 2024 at 01:26 am IST

More quotes

Company Profile

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to approved drugs. The Company’s principal business is the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). The primary active ingredient of the EP-104 products consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA). Its lead product candidate is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms and is used corticosteroid with systemic safety record. EP-104 is in Phase Ib/IIa clinical development.
Sector
Biotechnology & Medical Research
Calendar
10/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.73 CAD
Average target price
14.45 CAD
Spread / Average Target
+287.40%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EUPRAXIA PHARMACEUTICALS INC. Stock Eupraxia Pharmaceuticals Inc.
-31.47% 97.06M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EPRX Stock